Matthew Taylor

Barclays analysts Jack Meehan and Matthew Taylor initiated coverage on the Life Science Tools & Diagnostics industry with a positive view. “The industry's innovation has rewarded shareholders with impressive growth in-and-out of the cycle, where recent end-market data points...

Shares of C.R. Bard (NYSE: BCR) are down following a report from Barclays regarding test results and the Medtronic (NYSE: MDT) and Covidien (NYSE: COV) merger, which may “create a headwind.” Analyst Matthew Taylor writes about difficulties, “Based on our channel checks and...